SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer

Current Opinion in Biotechnology

Volumn 15, Issue 1, 2004, Pages 24-30

  Petricoin, Emanuel F ^a   Liotta, Lance A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; CANCER DIAGNOSIS; CELL COMMUNICATION; EARLY DIAGNOSIS; FUTUROLOGY; HUMAN; MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT;

EID: 1242328742     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2004.01.005     Document Type: Review

References (22)

1. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics. 1:2002;845-867 The number of new FDA approved biomarkers has dropped off substantially over the past decade despite advances in genomics.
2. Ward J.B. Jr., Henderson R.E. Identification of needs in biomarker research. Environ Health Perspect. 104(Suppl 5):1996;895-900.
3. Tirumalai R.S., Chan K.C., Prieto D.A., Issaq H.J., Conrads T.P., Veenstra T.D. Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics. 2:2003;1096-1103 Details the first comprehensive analysis of the low molecular weight region of the serum proteome, an unexplored information archive that may contain large numbers of biomarkers.
4. Kantor A.B. Comprehensive phenotyping and biological marker discovery. Dis. Markers. 18:2002;91-97.
5. McDonald W.H., Yates J.R. III Shotgun proteomics and biomarker discovery. Dis. Markers. 18:2002;99-105.
6. Cojocel C., Maita K., Baumann K., Hook J.B. Renal processing of low molecular weight proteins. Pflugers Arch. 401:1984;333-339.
7. Maack T. Renal handling of low molecular weight proteins. Am. J. Med. 58:1975;57-64.
8. Liotta L.A., Ferrari M., Petricoin E. Clinical proteomics: written in blood. Nature. 425:2003;905 MS-generated proteomic patterns are now known to be comprised mostly of protein fragments and cleavage products generated as a result of on-going physiologic processes. In the future, harvesting nanoparticles designed to act as biomarker attractants could be used in vivo or ex vivo as 'molecular mops' that can be directly analyzed by MS.
9. Mehta A., Ross S., Lowenthal M.S., Fusaro V., Fishman D.A., Petricoin E.F., Liotta L.A. Biomarker amplification by serum carrier protein binding. Dis. Markers. 19:2003;1-10 Biomarker amplification is found to take place because low molecular weight peptide and protein fragments bind to carrier proteins that enrich and increase the overall abundance of these biomarkers over time.
10. Petricoin E.F. III, Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577 Serum Proteomic Pattern Diagnostics, where pattern recognition tools are coupled to MS profiles, is described for the first time, with the technology developed and utility shown for early stage ovarian cancer detection.
11. Petricoin E.F. III, Mills G.B., Kohn E.S., Liotta L.A. Proteomic patterns in serum and identification of ovarian cancer. Lancet. 360:2002;170-171.
12. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48:2002;1296-1304 Description of highly accurate serum-based proteomic patterns for breast cancer detection.
13. Petricoin E.F. III, Ornstein D.K., Paweletz C.P., Ardekani A., Hackett P.S., Hitt B.A., Velassco A., Trucco C., Wiegand L., Wood K.et al. Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 94:2002;1576-1578 Description of highly accurate serum-based proteomic patterns for prostate cancer detection and discrimination from prostatitis and BPH even in the diagnostic indeterminate range of PSA (4-10 ng/ml).
14. Adam B.L., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., Semmes O.J., Schellhammer P.F., Yasui Y., Feng Z., Wright G.L. Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62:2002;3609-3614 Description of highly accurate serum-based proteomic patterns for prostate cancer detection and discrimination from prostatitis and BPH.
15. Conrads T.P., Zhou M., Petricoin E.F. III, Liotta L., Veenstra T.D. Cancer diagnosis using proteomic patterns. Expert Rev. Mol. Diagn. 3:2003;411-420 Description of high-resolution QqTOF MS proteomic patterns for increased accuracy of ovarian cancer detection.
16. Petricoin E. III, Liotta L.A. Counterpoint: the vision for a new diagnostic paradigm. Clin. Chem. 49:2003;1276-1278.
17. Petricoin E.F., Liotta L.A. Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin. Chem. 49:2003;533-534.
18. Hingorani SR, Petricoin EF III, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA et al.: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse cancer cell. 2003, 10:6-21.
19. Holland JH: Adaptation in Natural and Artificial Systems: an Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence. 3rd Edition. Cambridge, MA: MIT Press; 1994.
20. Kohonen T. Self-organizing formation of topologically correct feature maps. Biol. Cybern. 43:1982;59-69.
21. Kohonen T. The self-organizing map. Proc. IEEE. 78:1990;1464-1480.
22. Pattern classification by distance functions. In Pattern Recognition Principles. Edited by Tou JT, Gonzalez R: Reading, MA: Addison Weley Publishing Company, 1974;75-109.